Eli Lilly Lifts Outlook on Soaring GLP-1 Demand — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Eli Lilly raised its sales and revenue outlook as demand for its GLP-1 weight-loss shot soared, linking the drug’s commercial momentum to stronger results.
- Eli Lilly shares popped after strong GLP-1 drug demand lifted results, while its CEO said the obesity market has room for ‘dramatic’ expansion.
Why it matters: ServiceNow investors saw the sharp downside reaction, while Eli Lilly shareholders received both a higher sales outlook and a stock pop. The contrast shows how strongly investors responded to company-specific earnings commentary, while Lilly’s CEO argues the obesity market has room for ‘dramatic’ expansion.
Ask SkimNews
